查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048024

苯磺酸氨氯地平市場 - 全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局分類，2021-2031年

Amlodipine Besylate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球苯磺酸氨氯地平市場預計將從 2025 年的 4.7057 億美元成長到 2031 年的 6.1881 億美元，複合年成長率為 4.67%。

苯磺酸氨氯地平是一種長效鈣離子通道阻斷劑，廣泛用於治療高血壓和慢性穩定型狹心症。市場成長的主要促進因素是全球心血管疾病發生率的上升（需要長期服藥）以及人口老化加劇。此外，價格低廉的學名藥的廣泛普及也促進了市場成長，確保了患者獲得藥物的機會，並提高了醫療保健系統的效率。根據美國可及藥品協會（Association for Accessible Medicines）的一份報告顯示，到2024年，學名藥將占美國所有處方箋的90%，這表明像苯磺酸氨氯地平這樣廣泛使用且價格合理的藥物在慢性病管理中發揮著至關重要的作用。

市場概覽
預測期 2027-2031
市場規模：2025年 4.7057億美元
市場規模：2031年 6.1881億美元
複合年成長率：2026-2031年 4.67%
成長最快的細分市場 冠狀動脈疾病
最大的市場 北美洲

然而，儘管需求穩定，但由於價格大幅下跌，市場面臨許多挑戰。市場上充斥著大量非專利藥生產商提供的苯磺酸氨氯地平，激烈的競爭給價格帶來了巨大的下行壓力。這種商品化嚴重擠壓了生產商的利潤空間，迫使他們依靠提高銷量來維持盈利，這可能會阻礙他們對這種重要藥物生產的進一步投資。

市場促進因素

全球苯磺酸氨氯地平市場的主要促進因素是高血壓和心絞痛在全球範圍內的日益普遍。氨氯地平作為鈣離子通道阻斷劑，作為第一線治療藥物，在高血壓管理中發揮至關重要的作用，從而降低中風和心肌梗塞的風險。由於大量患者需要每天服用藥物以預防急性心血管事件，市場需求正在迅速成長。根據世界衛生組織（WHO）於2025年9月發布的《全球高血壓報告》，到2024年，全球約有14億30至79歲的成年人患有高血壓。這種廣泛的盛行率確保了對有效降血壓治療的持續且龐大的需求，從而形成以銷售量為基礎的收入流，有助於緩解市場價格壓力。

同時，易患心血管疾病的老年人口快速成長，也顯著推動了市場發展。隨著老齡化，血管硬化和動脈僵硬程度增加，老年人需要使用血管擴張劑（例如苯磺酸氨氯地平）來有效控制收縮期高血壓。世界衛生組織（WHO）於2025年2月發布的《老化：全球人口》報告顯示，全球60歲以上人口預計將從2023年的11億增加到2030年的14億。這一人口結構變化確保了慢性病治療藥物消費群的擴大，從而影響了製造商的策略。西普拉有限公司於2025年4月發布的《2024-2025年度報告》進一步強調了這一行業趨勢，指出其慢性病治療藥物的市場佔有率已佔其全部產品系列的61.5%。這凸顯了氨氯地平等長期維持治療藥物在藥品供應鏈中的戰略重要性。

市場挑戰

全球苯磺酸氨氯地平市場成長受到價格大幅下跌的嚴重阻礙，而價格下跌的直接原因是市場競爭高度飽和。作為一種廣泛使用的學名藥，苯磺酸氨氯地平幾乎已成為一種商品，許多生產商主要透過激進的價格策略來爭奪市場佔有率。這種激烈的競爭迫使企業不斷降價以贏得競標並與藥房簽訂契約，導致利潤率降至難以維持的水平。因此，投資報酬率的下降使得生產商不願擴大產能或進入市場，儘管患者需求旺盛，但市場擴張卻受到阻礙。

處方箋量增加與市場收入下降之間的這種背離是業界普遍存在的趨勢，對氨氯地平等大宗藥品造成了嚴重影響。例如，根據美國可及藥品協會（Association for Accessible Medicines）的一份報告，儘管處方箋總量增加且新產品不斷湧現，但到2025年，美國學名藥的總銷售額將比2019年減少64億美元。這種顯著的通縮壓力表明，雖然患者的用藥可及性有所提高，但製造商的經濟效益卻受到削弱，這直接阻礙了市場的貨幣擴張。

市場趨勢

全球苯磺酸氨氯地平市場正經歷重大變革，這主要得益於固定劑量組合藥物（FDC）療法的快速普及，製藥公司正致力於研發能夠提高患者用藥依從性和臨床療效的治療方法。除了單藥治療外，製藥公司也擴大將氨氯地平與其他降血壓藥（例如血管收縮素受體阻斷劑和利尿劑）聯合使用，以開發簡化的單片服用方案，方便合併多種疾病的患者。根據《藥學時報》報道，該領域的一項重要臨床進展是美國食品藥物管理局（FDA）於2025年6月核准了一種新的固定劑量複方製劑，該製劑由Telmisartan、氨氯地平和吲達帕胺組合藥物。這將是首個核准用於高血壓一線治療的三重藥物組合。

同時，向亞太新興市場的策略重心轉移已十分明顯。該地區醫療基礎設施的不斷改進和病患就醫便利性的提升，正推動企業營收的顯著成長。製藥公司正利用其在心血管領域的強大品牌知名度，積極開拓這些市場銷售量龐大的地區，以應對西方已開發市場普遍存在的市場飽和和價格壓力。近期的企業績效也進一步印證了這項區域策略。例如，根據 Lupin Limited 於 2025 年 7 月發布的《2024-2025 年綜合報告》，其在印度的循環系統部門累計超過 184.16 億盧比，實現了 12.6% 的成長率，遠超市場平均水平。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球苯磺酸氨氯地平市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 最終用途分類（高血壓、慢性穩定型狹心症、血管痙攣性心絞痛、冠狀動脈疾病、其他）
    • 按地區
    • 按公司（2025米）
  • 市場地圖

第6章：北美苯磺酸氨氯地平市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲氨氯地平苯磺酸鹽市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區苯磺酸氨氯地平市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲氨氯地平苯磺酸鹽市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美氨氯地平苯磺酸鹽市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球苯磺酸氨氯地平市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Zydus Cadila
  • Mankind Pharma Ltd.
  • Alembic Pharmaceuticals Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28280

The global Amlodipine Besylate market is projected to expand from USD 470.57 million in 2025 to USD 618.81 million by 2031, demonstrating a compound annual growth rate (CAGR) of 4.67%. Amlodipine Besylate, a long-acting calcium channel blocker, is extensively prescribed for treating hypertension and chronic stable angina. The market's growth is primarily fueled by the increasing global incidence of cardiovascular diseases and a growing elderly population, both requiring ongoing pharmacological treatment. Additionally, the widespread availability of affordable generic versions boosts the market by ensuring broad patient access and supporting healthcare system efficiency. In 2024, generic medicines constituted 90% of all prescriptions in the United States, as reported by the Association for Accessible Medicines, underscoring the vital role of high-volume, cost-effective drugs such as Amlodipine Besylate in managing chronic ailments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 470.57 Million
Market Size 2031USD 618.81 Million
CAGR 2026-20314.67%
Fastest Growing SegmentCoronary Artery Disease
Largest MarketNorth America

However, despite this consistent demand, the market confronts a significant hurdle due to severe price erosion. The market is saturated with numerous generic manufacturers offering Amlodipine Besylate, leading to intense competition that exerts substantial downward pressure on prices. This commoditization significantly limits revenue margins for manufacturers, compelling them to depend on high sales volumes to sustain profitability and potentially deterring further investment in the production of this crucial medication.

Market Driver

The primary driver of the Global Amlodipine Besylate Market is the increasing global prevalence of hypertension and angina pectoris. As a first-line calcium channel blocker, Amlodipine plays a critical role in managing high blood pressure, thereby lowering the risk of stroke and myocardial infarction. Demand is growing intensely due to the vast number of patients who require daily, lifelong medication to prevent acute cardiovascular events. The World Health Organization's 'Global Hypertension Report' in September 2025 indicated that approximately 1.4 billion adults aged 30-79 worldwide suffered from hypertension in 2024. This extensive prevalence guarantees a continuous, high-volume need for effective antihypertensive treatments, forming a volume-based revenue stream that helps mitigate the market's pricing pressures.

Simultaneously, the market is considerably strengthened by the swift expansion of the geriatric population, a group inherently more susceptible to cardiovascular comorbidities. The aging process, which includes stiffening of blood vessels and increased arterial rigidity, necessitates vasodilators such as Amlodipine Besylate for effective management of systolic hypertension in older individuals. According to the World Health Organization's 'Ageing: Global population' update from February 2025, the worldwide population aged 60 and above is expected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. This demographic shift ensures an expanding consumer base for chronic care medications, thereby influencing manufacturer strategies. Cipla Limited's 'Annual Report 2024-25' in April 2025 further highlights this industry focus, noting an improvement in the market share of chronic therapies to 61.5% of their total portfolio, which underscores the strategic importance of long-term maintenance drugs like Amlodipine within the pharmaceutical supply chain.

Market Challenge

The Global Amlodipine Besylate Market's value growth is significantly hindered by intense price erosion, a direct consequence of its highly saturated competitive environment. As a widely available generic pharmaceutical, Amlodipine Besylate has essentially become a commoditized product, with many manufacturers competing for market share primarily through aggressive pricing tactics. This fierce competition forces companies to continually reduce prices to win tenders and secure pharmacy contracts, pushing profit margins to unviable levels. As a result, the dwindling return on investment discourages manufacturers from increasing production capacity or entering the market, thus impeding the market's financial expansion despite high patient demand.

This disparity between growing prescription volumes and falling market revenue represents a well-established industry trend that severely affects commodity drugs such as Amlodipine. For example, the Association for Accessible Medicines reported that in 2025, the total value of generic sales in the United States had decreased by $6.4 billion since 2019, even though the overall volume of prescriptions and new product introductions had risen. This considerable deflationary pressure confirms that while patient access improves, the economic feasibility for manufacturers is compromised, directly restraining the market's monetary expansion.

Market Trends

The Global Amlodipine Besylate Market is undergoing a significant transformation driven by the rapid adoption of Fixed-Dose Combination (FDC) therapies, as manufacturers increasingly focus on regimens that improve medication adherence and clinical results. Moving beyond single-drug treatments, pharmaceutical companies are now frequently combining Amlodipine with other antihypertensive agents, such as angiotensin receptor blockers and diuretics, to develop simplified single-pill solutions for patients with multiple comorbidities. A notable clinical advancement in this area was the U.S. Food and Drug Administration's approval of a novel fixed-dose combination of telmisartan, amlodipine, and indapamide in June 2025, as reported by Pharmacy Times, marking the first triple-combination therapy approved for initial hypertension treatment.

Simultaneously, a clear strategic redirection towards emerging markets in the Asia-Pacific region is apparent, where expanding healthcare infrastructure and increased patient access are stimulating considerable revenue growth. Manufacturers are actively targeting these territories with high sales volumes to counteract the market saturation and pricing pressures prevalent in developed Western economies, capitalizing on strong brand recognition within the cardiology sector. This geographical focus is substantiated by recent corporate results; for example, Lupin Limited's 'Integrated Report 2024-25' in July 2025 indicated that its cardiology segment in India generated over INR 18,416 million in revenue, achieving a 12.6% growth rate that substantially surpassed the overall market average.

Key Market Players

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Zydus Cadila
  • Mankind Pharma Ltd.
  • Alembic Pharmaceuticals Ltd.

Report Scope

In this report, the Global Amlodipine Besylate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amlodipine Besylate Market, By Sales Channel

  • Direct
  • Indirect

Amlodipine Besylate Market, By End Use

  • Hypertension
  • Chronic Stable Angina
  • Vasospastic Angina
  • Coronary Artery Disease
  • Others

Amlodipine Besylate Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amlodipine Besylate Market.

Available Customizations:

Global Amlodipine Besylate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Amlodipine Besylate Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Hypertension, Chronic Stable Angina, Vasospastic Angina, Coronary Artery Disease, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Amlodipine Besylate Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Amlodipine Besylate Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Amlodipine Besylate Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Amlodipine Besylate Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Amlodipine Besylate Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Amlodipine Besylate Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Amlodipine Besylate Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Amlodipine Besylate Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Amlodipine Besylate Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Amlodipine Besylate Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Amlodipine Besylate Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Amlodipine Besylate Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Amlodipine Besylate Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Amlodipine Besylate Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Amlodipine Besylate Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Amlodipine Besylate Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Amlodipine Besylate Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Amlodipine Besylate Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Amlodipine Besylate Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Amlodipine Besylate Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. South America Amlodipine Besylate Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Amlodipine Besylate Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Amlodipine Besylate Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Amlodipine Besylate Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Amlodipine Besylate Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Teva Pharmaceutical Industries Ltd.
  • 15.3. Viatris Inc.
  • 15.4. Sandoz International GmbH
  • 15.5. Dr. Reddy's Laboratories Ltd.
  • 15.6. Sun Pharmaceutical Industries Ltd.
  • 15.7. Cipla Ltd.
  • 15.8. Zydus Cadila
  • 15.9. Mankind Pharma Ltd.
  • 15.10. Alembic Pharmaceuticals Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer